New therapeutic combination to slow resistant sarcomas

July 10, 2014
Researchers Òscar Martínez-Tirado and Javier García del Muro are shown.. Credit: IDIBELL

Researchers at sarcomas research group at the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) have been tested in 19 patients a new therapeutic combination to combat resistant sarcomas. The clinical trial results, which indicate that the new treatment could stabilize the growth of these tumors have been published this week in the British Journal of Cancer.

Sarcomas

Sarcomas are a rare type of tumor and complex since there are several subtypes. It can affect from children to older ages. It is usually diagnosed in advanced and very little localized phases. So the 50% cured with major surgeries and localized treatment. But the other 50% is resistant to conventional therapies and ends metastasizing.

The IDIBELL research group in sarcomas, led by Oscar Martinez-Tirado, investigate to test new drugs or new combinations of drugs that could be more effective against these tumors and for that works closely with the coordinator of the Unit of Sarcomas at ICO, Javier García del Muro. This teamwork joins the most basic research to the most clinical and has led in this case to bring the results of research from bench to bedside.

Conventional chemotherapy and targeted therapy

Researchers tested different combinations of conventional with new drugs aimed at molecular targets in cell sarcomas and decided to try in mice a combination of conventional chemotherapy used to treat these tumors and rapamycin, a drug that acts specifically in mTOR, an altered protein in various types of cancer.

"With the results in the cell lines we thought it was the best option to test in mice," said Martinez-Tirado "but the truth is that the results in animals were spectacular. In mice that had the tumor and we gave to them this combination, the tumor stopped growing and weeks after stopping treatment it was not recovered, as it does if we treat them with chemotherapy alone or only with rapamycin. "

Responsible for this phase I clinical trial has been Javier García del Muro. It has been tested this new combination in nineteen , most of sarcoma but also included patients with other tumor types that have no treatment. "Although Phase I trials are used to determine the recommended dose and discard toxicities, we have seen that the combination is active in various types, as we have seen prolongated stabilizations in advanced and resistant tumors to chemotherapy" .

With these encouraging results, the group has launched a phase II clinical trial. "We have completed the recruitment of patients, in this case, only , to test whether this combination really works in these patients and whether it is better than current treatments."

Explore further: Research team identifies mechanism of chemotherapy resistance in inflammatory breast cancer

More information: Juan Martin-Liberal, Marta Gil-Martín, Miguel Sáinz-Jaspeado, Nuria Gonzalo, Raul Rigo, Helena Colom, Carmen Muñoz, Oscar M Tirado and Xavier García del Muro. Phase I study of sirolimus plus gemcitabine in solid tumors. British Journal of Cancer. Epub ahead July 8th.

Related Stories

Research team identifies mechanism of chemotherapy resistance in inflammatory breast cancer

July 8, 2014
Researchers at Roswell Park Cancer Institute (RPCI) have identified a mechanism of breast cancer cells that leads to chemotherapy resistance in inflammatory breast cancer. These preclinical findings, published online ahead ...

Two-drug combo more effective in treating sarcomas, study shows

April 9, 2013
Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have found that when given together, a two-drug combination acts synergistically in test animals modeled with sarcoma tumors. They report ...

Researchers find sarcoma tumor immune response with combination therapy

March 1, 2012
A team of 18 researchers at Moffitt Cancer Center in Tampa, Fla., have found that treating high-risk, soft tissue sarcoma patients with a combination of implanted dendritic cells (immune system cells) and fractionated external ...

Genomic testing links 'exceptional' drug response to rare mutations in bladder cancer

March 13, 2014
A patient with advanced bladder cancer in a phase I trial had a complete response for 14 months to a combination of the targeted drugs everolimus and pazopanib, report scientists led by a Dana-Farber Cancer Institute researcher, ...

Carbon ion radiotherapy safe and effective for treating inoperable spinal tumors

August 12, 2013
A new analysis has found that a type of radiation therapy called carbon ion radiotherapy can control cancer growth and prolong survival in patients with spinal tumors. Published early online in Cancer, a peer-reviewed journal ...

UIC conducts phase I drug study for advanced pancreatic cancer

June 3, 2014
Researchers at the University of Illinois at Chicago are conducting a clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer.

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.